



## Corporate Profile

CytomX Therapeutics develops Probody™ therapeutics for the treatment of cancer. Probody therapeutics are fully recombinant masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment. The Probody approach is designed to blunt systemic toxicities associated with antibodies and expand the therapeutic window of these drugs, potentially unlocking new therapeutic targets. The Company is initially focusing this highly innovative platform to discover and develop new immunotherapy and antibody drug conjugate therapies to treat areas of major unmet medical need in oncology.

## Stock Performance

### CTMX (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Financial Status Indicator	C
Price	<b>\$20.50</b>
Change (%)	<b>▼ 0.76 (3.57%)</b>
Volume	116,392
52 Week Low	\$9.87
Market Cap	\$755,781,024
Rolling EPS	-1.70
PE Ratio	0
Shares Outstanding	36,867,367

Data as of 10/16/17 4:00 p.m. ET



## Recent Headlines

10/16/17

CytomX Announces Upcoming Poster Presentations at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference

10/03/17

Amgen And CytomX Therapeutics Announce Strategic Collaboration In Immuno-Oncology

09/13/17

CytomX to Present at the Cantor Fitzgerald Healthcare Conference

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form	Description
10/06/17	4	Statement of changes in beneficial ownership of securities
10/06/17	4	Statement of changes in beneficial ownership of securities
10/06/17	4	Statement of changes in beneficial ownership of securities
10/04/17	4	Statement of changes in beneficial ownership of securities

Data provided by Nasdaq. Minimum 15 minutes delayed.